Dicerna Announces Fourth Quarter and Full Year 2015 Financial and Operational Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Jefferies Reiterates Buy on Dicerna Pharma (DRNA) Following 4Q - PT to $19
March 11, 2016 9:38 AM ESTJefferies maintained a Buy rating on Dicerna Pharmaceuticals (NASDAQ: DRNA), and cut the price target to $19.00 (from $25.00), following the company's 4Q. DRNA reported a Narrower 4Q15 net loss of $15.7M, compared to Jefferies' net loss estimate of $18.1M.
Analyst Eun Yang... More
Dicerna Pharma (DRNA) Tops Q4 EPS by 8c
March 10, 2016 4:10 PM ESTDicerna Pharma (NASDAQ: DRNA) reported Q4 EPS of ($0.76), $0.08 better than the analyst estimate of ($0.84).
For earnings history and earnings-related data on Dicerna Pharma (DRNA) click here.
... More